These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38371581)

  • 1. Tofacitinib 2% Gel in Childhood Vitiligo: Report of a Case of Significant Improvement.
    Das A; Chatterjee M
    Indian J Dermatol; 2023; 68(6):705-706. PubMed ID: 38371581
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy.
    Perche P; Purvis C; Pichardo R
    J Drugs Dermatol; 2022 Dec; 21(12):1366-1368. PubMed ID: 36468955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient.
    Berbert Ferreira S; Berbert Ferreira R; Neves Neto AC; Assef SMC; Scheinberg M
    Case Rep Dermatol; 2021; 13(1):190-194. PubMed ID: 34703426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
    Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
    An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib combined with melanocyte protector α-MSH to treat vitiligo through dextran based hydrogel microneedles.
    Liang J; Yu Y; Li C; Li Q; Chen P; Li W; Liu W; Li Z; Liu Y; Zhang S; Zhang X
    Carbohydr Polym; 2023 Apr; 305():120549. PubMed ID: 36737198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice.
    Song H; Hu Z; Zhang S; Yang L; Liu Y; Wang T
    Dermatol Ther; 2022 Nov; 35(11):e15821. PubMed ID: 36114601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib in the treatment of refractory eczemas - a case series.
    Duraisamy P; Jagadeesan S; Thomas J
    J Dermatolog Treat; 2022 Sep; 33(6):2873-2875. PubMed ID: 35642323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays.
    Hesham H; Rady M; Hathout RM; Abdel-Halim M; Mansour S
    Int J Pharm; 2022 Dec; 629():122387. PubMed ID: 36375683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
    Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
    Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant improvement of vitiligo with oral tofacitinib treatment.
    Aickara DJ; Patel S; Rosen J; Alonso-Llamazares J
    Int J Dermatol; 2023 Jun; 62(6):e358-e360. PubMed ID: 35816261
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis.
    Tajalli M; Kabir S; Vance TM; Qureshi AA
    Clin Case Rep; 2020 May; 8(5):819-822. PubMed ID: 32477525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
    Gianfaldoni S; Tchernev G; Wollina U; Roccia MG; Fioranelli M; Lotti J; Rovesti M; Satolli F; Valle Y; Goren A; Tirant M; Situm M; Kovacevic M; França K; Lotti T
    Open Access Maced J Med Sci; 2018 Jan; 6(1):46-48. PubMed ID: 29483979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repigmentation of acral vitiligo with tofacitinib combined with NB-UVB phototherapy: A case report.
    Sun XK; Xu AE
    Australas J Dermatol; 2023 Nov; 64(4):571-572. PubMed ID: 37635652
    [No Abstract]   [Full Text] [Related]  

  • 18. Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow-band UVB: A case report of 2-year follow-up.
    Xu Z; Xing X; Xuan Y; Xiang LF; Zhang C
    Photodermatol Photoimmunol Photomed; 2023 Nov; 39(6):663-666. PubMed ID: 37409472
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose tofacitinib with 308-nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo.
    Fang WC; Lin SY; Huang SM; Lan CE
    Clin Exp Dermatol; 2022 Apr; 47(4):782-783. PubMed ID: 34923664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature.
    Abdelmaksoud A; Dave DD; Lotti T; Vestita M
    Dermatol Ther; 2019 Sep; 32(5):e13013. PubMed ID: 31265164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.